Actimis Pharmaceuticals is Therapeutic Devices in United States that focus on obstructive pulmonary disease business. Founded in 2004. They cover business area such as developer, small molecule therapeutic, respiratory, inflammatory and autoimmune disease, its therapeutic, asthma, chronic obstructive pulmonary disease, COPD, inflammatory dermatosis, inflammatory bowel disease, arthritis enable physician, these disease.
2004
( 20 years old in 2024 )
Obstructive Pulmonary Disease
-
10835 Road To The Cure
Suite 200
San Diego, CA 92121
United States
Private
developersmall molecule therapeuticrespiratory, inflammatory and autoimmune diseaseits therapeuticasthmachronic obstructive pulmonary diseaseCOPDinflammatory dermatosisinflammatory bowel diseasearthritis enable physicianthese disease
* We use standard office opening hours in near Actimis Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Actimis Pharmaceuticals is Therapeutic Devices business from United States that founded in 2004 (20 years old in 2024), Actimis Pharmaceuticals business is focusing on Obstructive Pulmonary Disease.
Actimis Pharmaceuticals headquarter office and corporate office address is located in 10835 Road To The Cure Suite 200 San Diego, CA 92121 United States.
Actimis Pharmaceuticals was founded in United States.
In 2024, Actimis Pharmaceuticals is currently focus on obstructive pulmonary disease sector.
Above is snippet of Google Trends for "obstructive pulmonary disease" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Actimis Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
